Evaluation of HER-2/neu Overexpression in Gastric Carcinoma using a Tissue Microarray

  • Rakhshani, Nasser (Department of Pathology, Firoozgar Hospital, Iran University of Medical Sciences) ;
  • Kalantari, Elham (Oncopathology Research Center and Department of Pathology, School of Medicine, Iran University of Medical Sciences) ;
  • Bakhti, Hadi (Department of Pathology, Firoozgar Hospital, Iran University of Medical Sciences) ;
  • Sohrabi, Masoud Reza (Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences) ;
  • Mehrazma, Mitra (Oncopathology Research Center and Department of Pathology, School of Medicine, Iran University of Medical Sciences)
  • 발행 : 2014.10.11


Background: Amplification and overexpression of human epidermal growth factor receptor 2 (HER2/neu) oncogene has considerable prognostic value in breast and gastric cancers. This study aimed to evaluate the frequency, overexpression pattern, clinical significance, and concordance between the results for protein expression and gene amplification of HER-2/neu in gastric and gastro-esophageal junction carcinomas. Materials and Methods: In this study, 101 gastric tissue samples which were included in tissue microarray were immunohistochemically examined for overexpression of HER2/neu. Chromogenic in situ hybridization (CISH) was used for HER-2/neu amplification. The correlation of HER2/neu amplification with clinicopathological parameters was also assessed. In addition, concordance between CISH and IHC was detected. Results: This study demonstrated a significant difference in the overexpression of HER2/neu in gastric tumors. The overexpression of HER2/neu was significantly higher in intestinal type, poorly differentiated grade, large size ($5cm{\leq}$) and positive nodal involvement tumors (p-value=0.041, 0.015, 0.038 and 0.071, respectively). Also, amplification of HER2/neu according to CISH test, had a significant positive correlation with tumor size and tumor type (p-value=0.018 and 0.058, respectively).Concordance between CISH and IHC was 76.9% in 101 evaluable samples. Conclusions: IHC/CISH differences were attributed to basolateral membranous immunoreactivity of glandular cells resulting in incomplete membranous reactivity and/or a higher rate of tumor heterogeneity in gastric cancers compared to breast cancers. Therefore, this can be a potential marker for targeted therapy of malignant gastric tumors.


  1. Allgayer H, Babic R, Gruetzner KU,et al (2000). c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol, 18, 2201-2209.
  2. Chen B, Luo RC, Cui F, Qian XY (2006). Association of HER-2/neu expression with prognosis of gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao, 26, 344-7.
  3. Choi JS, Kim MA, Lee HE, Lee HS, Kim WH (2009). Mucinous gastric carcinomas. Cancer, 115, 3581-90.
  4. Eltze E, Wulfing C,Von Struensee D, et al (2005). Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol, 26, 1525-31.
  5. Ghaderi A, Vasei M, Maleck-Hosseini SA, et al (2002). The expression of c-erbB-1 and c-erbB 2 in Iranian patients with gastric carcinoma. Pathol Oncol Res, 8, 252-6.
  6. Hetzel DJ, Wilson TO, Keeney GL, et al (1992). HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol, 47, 179-185.
  7. Gheytanchi E, Mehrazma M, Madjd Z (2014). Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma. Asian Pac J Cancer Prev, 15, 3065.
  8. Gravalos C, Jimeno A (2008). HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol, 19, 1523-9.
  9. Hanna WM, wok KK (2006). Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod pathol, 19, 481-7.
  10. Hirashima N, Takahashi W, Yoshii S, Yamane T, Ooi A (2001). Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol, 14, 556-62.
  11. Hofmann M, Stoss O, Shi D, et al (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 52, 797-805.
  12. Ishida T, Tsujisaki M, Hanzawa Y, et al (1994). Significance of erb B-2 gene product as a target molecule for cancer therapy. Scandinavian J Immunol, 39, 459-466.
  13. Keymoosi H, Gheytanchi E, Asgari M, Shariftabrizi A, Madjd Z (2013). ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Asian Pac J Cancer Prev, 15, 2013-20.
  14. Kiessling R, Wei WZ, Herrmann F, et al (2002). Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res, 85, 101-44.
  15. Koeppen HKW, Wright BD, Burt AD, et al (2001). Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology, 38, 96-104.
  16. Okines AFC, Cunningham D (2010). Trastuzumab in gastric cancer. Eur J Cancer, 46, 1949-1959.
  17. Madjd Z, Ramezani B, Molanae S, Asadi-Lari M (2012). High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. Asian Pac J Cancer Prev, 13, 2973-8.
  18. Madjd Z, Akbari ME, Zarnani AH, et al (2014). Expression of EMSY, a novel BRCA2-link protein, is associated with lymph node metastasis and increased tumor size in breast carcinomas. Asian Pac J Cancer Prev, 15, 1783-9.
  19. Mehrazma M, Madjd Z, Kalantari E, et al (2013). Expression of stem cell markers, CD133 and CD44, in pediatric solid tumors: a study using tissue microarray. Fetal Pediatr Pathol, 32, 192-204.
  20. Ooi A, Kobayashi M, Mai M, Nakanishi I (1998). Amplification of c-erbB-2 in gastric cancer: detection in formalinfixed, paraffin-embedded tissue by fluorescence in situ hybridization. Lab invest, 78, 345-51.
  21. Reichelt U, Duesedau P, Tsourlakis MCh, et al (2007). Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol, 20, 120-9.
  22. Ross JS, McKenna BJ (2001). The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Investigation, 19, 554-68.
  23. Ruschoff J, Dietel M, Baretton G, et al (2010). HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing. Virchows Archiv, 457, 299-307.
  24. Ruschoff J, Hanna W, Bilous M, et al (2012). HER2 testing in gastric cancer: a practical approach. Mod Pathol, 25, 637-650.
  25. Schuell B, Gruenberger T, Scheithauer W, Zielinski Ch, Wrba F (2006). HER 2/neu protein expression in colorectal cancer. BMC Cancer, 6, 123.
  26. Takehana T, Kunitomo K, Kono K, et al (2002). Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer, 98, 833-7.
  27. Shinohara H, Morita S, Kawai M, et al (2002). Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J Surg Res, 102, 169-177.
  28. Slamon DJ, Leyland-Jones B, Shak S, et al (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783-92.
  29. Smith I, Procter M, Gelber RD, et al (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet, 369, 29-36.
  30. Tanner M, Hollmen M, Junttila TT, et al (2005). Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II$\alpha$ gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol, 16, 273-278.
  31. Tapia C, Glatz K, Novotny H, et al (2007). Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol, 20, 192-198.
  32. Thompson SK, Sullivan TR, Davies R, Ruszkiewicz AR (2011). Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol, 18, 2010-2017.
  33. Tokunaga A, Onda M, Okuda T, et al (1995). Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbb-2 in human gastric cancer. Cancer, 75, 1418-25.<1418::AID-CNCR2820751505>3.0.CO;2-Y
  34. Yano T, Ochiai A, Doi T, et al (2004). Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol, 22, 4053.
  35. Yano T, Ohtsu A, Boku N, et al (2006). Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncology Reports, 15, 65-71.

피인용 문헌

  1. Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms in Gall Bladder Cancer vol.16, pp.14, 2015,
  2. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma vol.16, pp.17, 2015,
  3. High Quality Tissue Miniarray Technique Using a Conventional TV/Radio Telescopic Antenna vol.16, pp.3, 2015,
  4. Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma vol.32, pp.10, 2017,
  5. Gene delivery by a cationic and thermosensitive nanogel promoted established tumor growth inhibition vol.10, pp.10, 2015,